Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1167 plus bevacizumab in recurrent ovarian cancer
CTR20240646Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of M9466, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui Therapeutics. Started Mar 2024; status: active.
02
Drugs
M9466bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20240646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240646.